Haim Bio _{하임바이오}, a venture company for new bio drugs, entered into a strategic business alliance agreement with Blue Green Investment _{블루그린 인베스트먼트} on Aug. 31 to preempt cancer metabolic regulatory chemotherapy market.

Haim Bio is set to concentrate on the development of the world's first fourth- generation anti-cancer drug through its strategic alliance with Bluegreen.

Cancer metabolism drug is a new cancer treatment agent that blocks the metabolic pathway of cancer cells and necrotizes cancer cells. The drug targets the energy metabolism of cancer cells and starves the cancer cells without affecting healthy cells.

This technology is widely applicable to incurable, rare and recurrent cancers and is expected to expand its therapeutic range.

The new drug applies technologies co-developed by three professors -- Professor Kim Soo-yeol _김수열 of the National Cancer Center _{국립암센터} and Professors Jung Jae-ho _정재호 and Kang Suk-goo _강석구 of the Severance Hospital _{세브란스병원} — regarding lung, stomach and brain cancer in 2016.

It also applied the cancer-mediated chemotherapeutic drug technology developed by the National Cancer Center's pancreatic cancer drug development team in 2017.

The drug is currently in nonclinical trial and is preparing for clinical trials, a company official said.